Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P51610

UPID:
HCFC1_HUMAN

ALTERNATIVE NAMES:
C1 factor; CFF; VCAF; VP16 accessory protein

ALTERNATIVE UPACC:
P51610; Q6P4G5

BACKGROUND:
The protein Host cell factor 1, with aliases such as CFF and VP16 accessory protein, is integral to transcriptional coactivation and repression, cell cycle progression, and histone modification. It serves as a coactivator for key transcription factors and tethers chromatin modifying complexes, playing a critical role in the regulation of gene expression. HCFC1's function extends to facilitating the transition from G1 to S phase of the cell cycle and modulating insulin secretion by regulating pancreatic beta-cell growth.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in the pathogenesis of methylmalonic aciduria and homocystinuria, cblX type, HCFC1 represents a promising target for drug discovery efforts. The exploration of HCFC1's functions and mechanisms offers a pathway to novel treatments for this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.